CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research and development expenses	$ 4,568	$ 2,281	$ 12,927	$ 6,378
Less: Participation by the Office of the Chief Scientist	(367)	(716)	(1,797)	(1,898)
Research and development expenses, net	4,201	1,565	11,130	4,480
Non-recurring research and development expenses resulting from acquisition	8,170	0	8,170	0
General and administrative expenses	2,996	2,305	10,832	8,262
Operating loss	(15,367)	(3,870)	(30,132)	(12,742)
Financial expenses	(1,192)	(64)	(1,431)	(92)
Financial income	44	896	45	605
Loss before taxes on income	(16,515)	(3,038)	(31,518)	(12,229)
Taxes on income	6	2	11	8
Loss	$ (16,521)	$ (3,040)	$ (31,529)	$ (12,237)
Basic loss per share (in dollars per share)	$ (0.66)	$ (0.16)	$ (1.27)	$ (0.65)
Diluted loss per share (in dollars per share)	$ (0.66)	$ (0.21)	$ (1.30)	$ (0.68)
Weight average number of common stock used in computing basic loss per share (in shares)	24,982,577	18,817,557	24,911,481	18,716,109
Weight average number of common stock used in computing diluted loss per share (in shares)	24,982,577	18,938,723	24,974,128	18,863,403